# Arimoclomol in Amyotropic Lateral Sclerosis

> **NCT03491462** · PHASE3 · COMPLETED · sponsor: **ZevraDenmark** · enrollment: 245 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Arimoclomol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03491462
- **Lead sponsor:** ZevraDenmark
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-31
- **Primary completion:** 2020-12-18
- **Final completion:** 2020-12-18
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2023-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03491462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03491462, "Arimoclomol in Amyotropic Lateral Sclerosis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03491462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*